{"id":758402,"date":"2023-05-12T07:22:38","date_gmt":"2023-05-12T11:22:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/"},"modified":"2023-05-12T07:22:38","modified_gmt":"2023-05-12T11:22:38","slug":"autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/","title":{"rendered":"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA"},"content":{"rendered":"
\n

LONDON, May 12, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed\/refractory (r\/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 – 11, 2023, in Frankfurt.<\/p>\n\n\n\n\n\n
\n EHA Oral Presentation:<\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\n\n Safety and efficacy of Obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19CAR in relapsed\/refractory adult B-Cell acute lymphoblastic leukemia (r\/r B-ALL): Topline results of the pivotal FELIX study<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Session Title: <\/strong>Gene therapy and cellular immunotherapy – Clinical
Presentation ID:<\/strong>\u00a0\u00a0 S262
Session date and time: <\/strong>Saturday, June 10, 2023, 11:00 \u2013 11:15 EDT, 16:00 \u2013 16:15 BST
Session room: <\/strong>Harmonie 1
Presenting Author: <\/strong>Dr. Claire Roddie, MD, PhD, FRCPath,\u00a0Consultant Haematologist and Honorary Senior Lecturer,\u00a0Cancer Institute, University College London (UCL)<\/p>\n

\n About Autolus Therapeutics plc<\/strong>
\n
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.<\/p>\n

\n About obe-cel\u00a0(AUTO1)<\/strong>
\n
Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.\u00a0Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with Autolus\u2019 academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL. Autolus has progressed obe-cel to the FELIX trial, a pivotal trial for adult ALL.<\/p>\n

\n About <\/strong>
\n obe-cel<\/strong>
\n FELIX clinical trial<\/strong>
\n
Autolus\u2019 Phase 1b\/2 clinical trial of obe-cel has completed enrolment of adult patients with relapsed \/ refractory B-precursor ALL in the morphological cohort. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint is overall response rate, and the secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is designed to enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States,\u00a0United Kingdom\u00a0and\u00a0Europe. [NCT04404660]<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the continued development of Autolus\u2019 obe-cel program; the status of clinical trials (including, without limitation, expectations regarding the data that is being presented, the expected timing of data releases and development, as well as completion of clinical trials) and development timelines for the Company\u2019s product candidates. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus\u2019 preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing, and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus\u2019 business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus\u2019 actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus’ Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 7, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n

\n Contact: <\/strong>\n <\/p>\n

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com<\/a><\/p>\n

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com<\/u><\/a><\/p>\n

Alexandra Deschner
+32-490-58-35-23
a.deschner@autolus.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON, May 12, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed\/refractory (r\/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 – 11, 2023, in Frankfurt. EHA Oral Presentation: \u00a0 Title: Safety and efficacy of Obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19CAR in relapsed\/refractory adult B-Cell acute lymphoblastic leukemia (r\/r B-ALL): Topline results of the pivotal FELIX study \u00a0 \u00a0 Session Title: Gene therapy and cellular immunotherapy – ClinicalPresentation ID:\u00a0\u00a0 S262Session date and time: Saturday, … <\/p>\n

Continue reading “Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758402","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAutolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON, May 12, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed\/refractory (r\/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 – 11, 2023, in Frankfurt. EHA Oral Presentation: \u00a0 Title: Safety and efficacy of Obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19CAR in relapsed\/refractory adult B-Cell acute lymphoblastic leukemia (r\/r B-ALL): Topline results of the pivotal FELIX study \u00a0 \u00a0 Session Title: Gene therapy and cellular immunotherapy – ClinicalPresentation ID:\u00a0\u00a0 S262Session date and time: Saturday, … Continue reading "Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T11:22:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\\\/r B-ALL selected for an oral presentation at EHA\",\"datePublished\":\"2023-05-12T11:22:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/\"},\"wordCount\":846,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/\",\"name\":\"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\\\/r B-ALL selected for an oral presentation at EHA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=\",\"datePublished\":\"2023-05-12T11:22:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\\\/r B-ALL selected for an oral presentation at EHA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA - Market Newsdesk","og_description":"LONDON, May 12, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed\/refractory (r\/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 – 11, 2023, in Frankfurt. EHA Oral Presentation: \u00a0 Title: Safety and efficacy of Obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19CAR in relapsed\/refractory adult B-Cell acute lymphoblastic leukemia (r\/r B-ALL): Topline results of the pivotal FELIX study \u00a0 \u00a0 Session Title: Gene therapy and cellular immunotherapy – ClinicalPresentation ID:\u00a0\u00a0 S262Session date and time: Saturday, … Continue reading \"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-12T11:22:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA","datePublished":"2023-05-12T11:22:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/"},"wordCount":846,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/","name":"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=","datePublished":"2023-05-12T11:22:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODEzMyM1NTkyMDgyIzIwOTk2MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r\/r B-ALL selected for an oral presentation at EHA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758402"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}